Skip to Main Content

Checkpoint inhibitors like Keytruda and Opdivo can be incredibly powerful cancer-killing drugs — when they work, that is, which is less than 70% of the time. For years, scientists have hoped to find a way to identify a combination of therapies that might help these drugs work for a larger number of people.

New clinical trial results published Thursday in Science provide some of the strongest evidence yet for an unusual but promising mashup: pairing immunotherapy drugs with fecal microbiota transplants, or FMTs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!